PURPOSE: ACTG A5164 demonstrated that early antiretroviral therapy (ART) in HIV-infected patients with acute opportunistic infections (OIs) reduced death and AIDS progression compared to ART initiation 1 month later. We project the life expectancies, costs, and incremental cost-effectiveness ratios (ICERs) of these strategies. METHOD: using an HIV simulation model, we compared 2 strategies for patients with acute OIs: (1) an intervention to deliver early ART, and (2) deferred ART. Parameters from ACTG A5164 included initial mean CD4 count (47/microL), linkage to outpatient care (87%), and immune reconstitution inflammatory syndrome 1 month after ART initiation (7%). The estimated intervention cost was $1,650/patient. RESULTS: early ART lowered projected 1-year mortality from 10.4% to 8.2% and increased life expectancy from 10.07 to 10.39 quality-adjusted life-years (QALYs). Lifetime costs increased from $385,220 with deferred ART to $397,500 with early ART, primarily because life expectancy increased, producing an ICER of $38,600/QALY. Results were most sensitive to increased intervention cost and decreased virologic efficacy in the early ART strategy. CONCLUSIONS: an intervention to initiate ART early in patients with acute OIs improves survival and meets US cost-effectiveness thresholds. Programs should be developed to implement this strategy at sites where HIV-infected patients present with OIs.
PURPOSE:ACTG A5164 demonstrated that early antiretroviral therapy (ART) in HIV-infectedpatients with acute opportunistic infections (OIs) reduced death and AIDS progression compared to ART initiation 1 month later. We project the life expectancies, costs, and incremental cost-effectiveness ratios (ICERs) of these strategies. METHOD: using an HIV simulation model, we compared 2 strategies for patients with acute OIs: (1) an intervention to deliver early ART, and (2) deferred ART. Parameters from ACTG A5164 included initial mean CD4 count (47/microL), linkage to outpatient care (87%), and immune reconstitution inflammatory syndrome 1 month after ART initiation (7%). The estimated intervention cost was $1,650/patient. RESULTS: early ART lowered projected 1-year mortality from 10.4% to 8.2% and increased life expectancy from 10.07 to 10.39 quality-adjusted life-years (QALYs). Lifetime costs increased from $385,220 with deferred ART to $397,500 with early ART, primarily because life expectancy increased, producing an ICER of $38,600/QALY. Results were most sensitive to increased intervention cost and decreased virologic efficacy in the early ART strategy. CONCLUSIONS: an intervention to initiate ART early in patients with acute OIs improves survival and meets US cost-effectiveness thresholds. Programs should be developed to implement this strategy at sites where HIV-infectedpatients present with OIs.
Authors: M C Weinstein; S J Goldie; E Losina; C J Cohen; J D Baxter; H Zhang; A D Kimmel; K A Freedberg Journal: Ann Intern Med Date: 2001-03-20 Impact factor: 25.391
Authors: Mark Nelson; Keikawus Arastéh; Bonaventura Clotet; David A Cooper; Keith Henry; Christine Katlama; Jacob P Lalezari; Adriano Lazzarin; Julio S G Montaner; Mary O'Hearn; Peter J Piliero; Jacques Reynes; Benoit Trottier; Sharon L Walmsley; Calvin Cohen; Joseph J Eron; Daniel R Kuritzkes; Joep Lange; Hans-Jürgen Stellbrink; Jean-François Delfraissy; Neil E Buss; Lucille Donatacci; Cynthia Wat; Lynn Smiley; Martin Wilkinson; Adeline Valentine; Denise Guimaraes; Ralph Demasi; Jain Chung; Miklos P Salgo Journal: J Acquir Immune Defic Syndr Date: 2005-12-01 Impact factor: 3.731
Authors: Paul E Sax; Runa Islam; Rochelle P Walensky; Elena Losina; Milton C Weinstein; Sue J Goldie; Sara N Sadownik; Kenneth A Freedberg Journal: Clin Infect Dis Date: 2005-09-23 Impact factor: 9.079
Authors: J W Mellors; A Muñoz; J V Giorgi; J B Margolick; C J Tassoni; P Gupta; L A Kingsley; J A Todd; A J Saah; R Detels; J P Phair; C R Rinaldo Journal: Ann Intern Med Date: 1997-06-15 Impact factor: 25.391
Authors: S A Bozzette; G Joyce; D F McCaffrey; A A Leibowitz; S C Morton; S H Berry; A Rastegar; D Timberlake; M F Shapiro; D P Goldman Journal: N Engl J Med Date: 2001-03-15 Impact factor: 91.245
Authors: Samuel A Shelburne; Fehmida Visnegarwala; Jorge Darcourt; Edward A Graviss; Thomas P Giordano; A Clinton White; Richard J Hamill Journal: AIDS Date: 2005-03-04 Impact factor: 4.177
Authors: Andrew Zolopa; Janet Andersen; William Powderly; Alejandro Sanchez; Ian Sanne; Carol Suckow; Evelyn Hogg; Lauren Komarow Journal: PLoS One Date: 2009-05-18 Impact factor: 3.240
Authors: Bahati Mk Wajanga; Lauren E Webster; Robert N Peck; Jennifer A Downs; Kedar Mate; Luke R Smart; Daniel W Fitzgerald Journal: BMC Health Serv Res Date: 2014-12-03 Impact factor: 2.655
Authors: Brenda Crabtree-Ramírez; Yanink Caro-Vega; Bryan E Shepherd; Beatriz Grinsztejn; Marcelo Wolff; Claudia P Cortes; Denis Padgett; Gabriela Carriquiry; Valeria Fink; Karu Jayathilake; Anna K Person; Catherine McGowan; Juan Sierra-Madero Journal: PLoS One Date: 2016-06-07 Impact factor: 3.240
Authors: Antonella Cingolani; Alessandro Cozzi-Lepri; Adriana Ammassari; Cristina Mussini; Maria Alessandra Ursitti; Pietro Caramello; Gioacchino Angarano; Paolo Bonfanti; Andrea De Luca; Maria Stella Mura; Enrico Girardi; Andrea Antinori; Antonela D'Arminio Monforte Journal: PLoS One Date: 2014-02-27 Impact factor: 3.240